Literature DB >> 17179969

T cell-directed therapies: lessons learned and future prospects.

Eric H Liu1, Richard M Siegel, David M Harlan, John J O'Shea.   

Abstract

Agents interfering with T cell function are therapeutic mainstays for various autoimmune diseases and for transplant approaches to organ failure. The understanding of T cell biology has blossomed since the development of most agents now in use. Here we discuss T cell-specific agents now in use, others recently added to the therapeutic armamentarium and promising agents being investigated in clinical and preclinical studies. In addition, we reflect on the risks and benefits involved in the testing of such agents clinically, with examples of agents that have successfully been used in the clinic and agents that failed to reach therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17179969     DOI: 10.1038/ni1429

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  17 in total

Review 1.  T-cell activation and transplantation tolerance.

Authors:  Bhavana Priyadharshini; Dale L Greiner; Michael A Brehm
Journal:  Transplant Rev (Orlando)       Date:  2011-11-08       Impact factor: 3.943

2.  Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550).

Authors:  Jian-kang Jiang; Kamran Ghoreschi; Francesca Deflorian; Zhi Chen; Melissa Perreira; Marko Pesu; Jeremy Smith; Dac-Trung Nguyen; Eric H Liu; William Leister; Stefano Costanzi; John J O'Shea; Craig J Thomas
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

3.  Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice.

Authors:  Kelley M K Haarberg; Jun Li; Jessica Heinrichs; Dapeng Wang; Chen Liu; Crystina C Bronk; Kane Kaosaard; Alexander M Owyang; Sacha Holland; Esteban Masuda; Kin Tso; Bruce R Blazar; Claudio Anasetti; Amer A Beg; Xue-Zhong Yu
Journal:  Blood       Date:  2013-08-01       Impact factor: 22.113

Review 4.  HDAC inhibition and graft versus host disease.

Authors:  Sung Choi; Pavan Reddy
Journal:  Mol Med       Date:  2011-01-08       Impact factor: 6.354

Review 5.  GVHD prevention: an ounce is better than a pound.

Authors:  Pavan Reddy; Gérard Socié; Corey Cutler; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

Review 6.  The safety and side effects of monoclonal antibodies.

Authors:  Trevor T Hansel; Harald Kropshofer; Thomas Singer; Jane A Mitchell; Andrew J T George
Journal:  Nat Rev Drug Discov       Date:  2010-03-22       Impact factor: 84.694

Review 7.  Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects.

Authors:  Fanny Monneaux; Sylviane Muller
Journal:  Arthritis Res Ther       Date:  2009-06-30       Impact factor: 5.156

Review 8.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

9.  Pancreatic beta cell function persists in many patients with chronic type 1 diabetes, but is not dramatically improved by prolonged immunosuppression and euglycaemia from a beta cell allograft.

Authors:  E H Liu; B J Digon; B Hirshberg; R Chang; B J Wood; Z Neeman; A Kam; R A Wesley; S M Polly; R M Hofmann; K I Rother; D M Harlan
Journal:  Diabetologia       Date:  2009-05-06       Impact factor: 10.122

Review 10.  Current advances and travails in islet transplantation.

Authors:  David M Harlan; Norma Sue Kenyon; Olle Korsgren; Bart O Roep
Journal:  Diabetes       Date:  2009-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.